Academic Journal
Abstract P238: US Cost Savings Resulting from the Dronedarone-Associated Reduction in Cardiovascular Hospitalizations among Atrial Fibrillation/Flutter Patients in the ATHENA Trial: Full Study Analysis
| العنوان: | Abstract P238: US Cost Savings Resulting from the Dronedarone-Associated Reduction in Cardiovascular Hospitalizations among Atrial Fibrillation/Flutter Patients in the ATHENA Trial: Full Study Analysis |
|---|---|
| المؤلفون: | Reynolds, Matthew, Zimetbaum, Peter J, Diamand, Françoise, Jhaveri, Mehul, Lin, Jay, Plich, Adam |
| المصدر: | Circulation: Cardiovascular Quality and Outcomes ; volume 4, issue suppl_2 ; ISSN 1941-7713 1941-7705 |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health) |
| سنة النشر: | 2011 |
| الوصف: | Introduction: The ATHENA trial randomized atrial fibrillation/flutter (AF/AFL) patients (pts) with ≥1 other cardiovascular (CV) risk factors to dronedarone (n=2301) or placebo (n=2327), plus standard care. Dronedarone reduced the rate of first CV hospitalization over the study period (mean ± SD 21 ± 5 months). This analysis assesses, from a US perspective, potential cost savings from the reduction in overall (first + subsequent) CV hospitalizations in ATHENA. Methods: Using a cost analysis model, we applied hospitalization costs reported from a US cohort of AF/AFL pts to hospitalization events among the ATHENA population. Clinical inputs included all CV- and adverse event (AE)-related hospitalizations over the ATHENA study period. Cost inputs (2008 values) were (i) weighted mean CV hospitalization costs (non-fatal + fatal combined), categorised according to cause of admission, derived from claims data for a cohort of ATHENA-like AF/AFL pts (n=10,200) with Medicare supplemental insurance, and (ii) DRG costs of hospitalizations for AEs recorded in ATHENA. Cost variations were assessed using Monte Carlo sensitivity analysis. Results: In ATHENA, overall CV hospitalization rate fell by 25% with dronedarone (1177/2301 vs 1596/2327, dronedarone vs placebo arms). Based on the observed hospitalization rates and derived hospitalization costs (Table), overall cost savings with dronedarone were estimated at (mean ± SD) $1763 ± 207 per pt over the ATHENA study period. The estimated savings in CV hospitalization costs (mean $1777 per pt) heavily outweighed the added estimated AE hospitalization costs (mean $14 per pt). Sensitivity analysis showed that the cost offset was relatively stable (range $1023−$2596 over 10,000 cycles of random variation). Conclusions: Dronedarone reduced the overall CV hospitalization rate by 25% in the ATHENA population, resulting in estimated mean hospitalization-related cost savings of $1763 per pt over the study period. Cause of hospitalization Number of hospitalizations per 100 patients 1 ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1161/circoutcomes.4.suppl_2.ap238 |
| الاتاحة: | http://dx.doi.org/10.1161/circoutcomes.4.suppl_2.ap238 |
| رقم الانضمام: | edsbas.7EBB335F |
| قاعدة البيانات: | BASE |
| ResultId |
1 |
|---|---|
| Header |
edsbas BASE edsbas.7EBB335F 773 3 Academic Journal academicJournal 772.654235839844 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.7EBB335F&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => http://dx.doi.org/10.1161/circoutcomes.4.suppl_2.ap238# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Abstract P238: US Cost Savings Resulting from the Dronedarone-Associated Reduction in Cardiovascular Hospitalizations among Atrial Fibrillation/Flutter Patients in the ATHENA Trial: Full Study Analysis
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Reynolds%2C+Matthew%22">Reynolds, Matthew</searchLink><br /><searchLink fieldCode="AR" term="%22Zimetbaum%2C+Peter+J%22">Zimetbaum, Peter J</searchLink><br /><searchLink fieldCode="AR" term="%22Diamand%2C+Françoise%22">Diamand, Françoise</searchLink><br /><searchLink fieldCode="AR" term="%22Jhaveri%2C+Mehul%22">Jhaveri, Mehul</searchLink><br /><searchLink fieldCode="AR" term="%22Lin%2C+Jay%22">Lin, Jay</searchLink><br /><searchLink fieldCode="AR" term="%22Plich%2C+Adam%22">Plich, Adam</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Circulation: Cardiovascular Quality and Outcomes ; volume 4, issue suppl_2 ; ISSN 1941-7713 1941-7705 ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Ovid Technologies (Wolters Kluwer Health) ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2011 ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Introduction: The ATHENA trial randomized atrial fibrillation/flutter (AF/AFL) patients (pts) with ≥1 other cardiovascular (CV) risk factors to dronedarone (n=2301) or placebo (n=2327), plus standard care. Dronedarone reduced the rate of first CV hospitalization over the study period (mean ± SD 21 ± 5 months). This analysis assesses, from a US perspective, potential cost savings from the reduction in overall (first + subsequent) CV hospitalizations in ATHENA. Methods: Using a cost analysis model, we applied hospitalization costs reported from a US cohort of AF/AFL pts to hospitalization events among the ATHENA population. Clinical inputs included all CV- and adverse event (AE)-related hospitalizations over the ATHENA study period. Cost inputs (2008 values) were (i) weighted mean CV hospitalization costs (non-fatal + fatal combined), categorised according to cause of admission, derived from claims data for a cohort of ATHENA-like AF/AFL pts (n=10,200) with Medicare supplemental insurance, and (ii) DRG costs of hospitalizations for AEs recorded in ATHENA. Cost variations were assessed using Monte Carlo sensitivity analysis. Results: In ATHENA, overall CV hospitalization rate fell by 25% with dronedarone (1177/2301 vs 1596/2327, dronedarone vs placebo arms). Based on the observed hospitalization rates and derived hospitalization costs (Table), overall cost savings with dronedarone were estimated at (mean ± SD) $1763 ± 207 per pt over the ATHENA study period. The estimated savings in CV hospitalization costs (mean $1777 per pt) heavily outweighed the added estimated AE hospitalization costs (mean $14 per pt). Sensitivity analysis showed that the cost offset was relatively stable (range $1023−$2596 over 10,000 cycles of random variation). Conclusions: Dronedarone reduced the overall CV hospitalization rate by 25% in the ATHENA population, resulting in estimated mean hospitalization-related cost savings of $1763 per pt over the study period. Cause of hospitalization Number of hospitalizations per 100 patients 1 ... ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article in journal/newspaper ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1161/circoutcomes.4.suppl_2.ap238 ) Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => http://dx.doi.org/10.1161/circoutcomes.4.suppl_2.ap238 ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.7EBB335F ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1161/circoutcomes.4.suppl_2.ap238
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Abstract P238: US Cost Savings Resulting from the Dronedarone-Associated Reduction in Cardiovascular Hospitalizations among Atrial Fibrillation/Flutter Patients in the ATHENA Trial: Full Study Analysis
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Reynolds, Matthew
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Zimetbaum, Peter J
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Diamand, Françoise
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Jhaveri, Mehul
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Lin, Jay
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Plich, Adam
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Type] => published
[Y] => 2011
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-locals
[Value] => edsbas
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Circulation: Cardiovascular Quality and Outcomes ; volume 4, issue suppl_2 ; ISSN 1941-7713 1941-7705
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |